Suppr超能文献

PD-L1表达和CD8 + T细胞浸润在肺神经内分泌肿瘤中的预后意义

Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.

作者信息

Wang Haiyue, Li Zhongwu, Dong Bin, Sun Wei, Yang Xin, Liu Ruping, Zhou Lixin, Huang Xiaozheng, Jia Ling, Lin Dongmei

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, People's Republic of China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Central Laboratory, Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China.

出版信息

Diagn Pathol. 2018 May 22;13(1):30. doi: 10.1186/s13000-018-0712-1.

Abstract

BACKGROUND

Recent research supports a significant role of immune checkpoint inhibitors in the treatment of solid tumors. However, relevant reports for programmed death-ligand 1 (PD-L1) and CD8+ tumor-infiltrating lymphocytes (TILs) in pulmonary neuroendocrine tumors (PNETs) have not been fully studied. Therefore, we investigated PNETs for the expression of PD-L1 and infiltration by CD8+ TILs as well as the prognostic value of both factors.

METHODS

In total, 159 specimens of PNETs (35 TC, 2 AC, 28 LCNEC, 94 SCLC) were included in this study. Immunohistochemistry (IHC) was used to detect the expression of PD-L1 in these cases. Cases demonstrating ≥5% tumor cell expression or any expression (> 1%) of PD-L1 on immune cells were considered positive. CD8+ TILs both within stroma and tumor areas of invasive carcinoma were analyzed using whole-slide digital imaging. Manual regional annotation and machine cell counts were performed for each case.

RESULTS

Positive expression of PD-L1 was observed in 72 cases (45.3%), including 9 cases (5.7%) with expression exclusively on tumor cells, 46 cases (28.9%) with expression exclusively on immune cells, and 17 cases (10.7%) with the expression on tumor cells and immune cells. PD-L1 expression was associated with necrosis (p < 0.001), high pathologic grade (p < 0.001) and histologic type (p < 0.001). No correlation was observed with overall survival (OS) (p = 0.158) or progression-free survival (PFS) (p = 0.315). In contrast, higher CD8+ T cell density was associated with the absence of vascular invasion (p = 0.004), histologic type (p = 0.005), negative lymph node metastasis (p = 0.005) and lower clinical staging (p = 0.007). Moreover, multivariate analysis revealed that CD8+ stromal TIL was an independent prognostic factor for improved OS (p = 0.009) and PFS (p = 0.002).

CONCLUSION

PD-L1 was expressed in approximately half of the PNETs. The majority of the expression was observed in immune cells. Positive expression of PD-L1 showed no correlation with OS or PFS, while higher CD8+ TILs within stroma was proved to be an independent prognostic factor for favorable OS and PFS of PNETs.

摘要

背景

近期研究支持免疫检查点抑制剂在实体瘤治疗中发挥重要作用。然而,关于程序性死亡配体1(PD-L1)和CD8+肿瘤浸润淋巴细胞(TILs)在肺神经内分泌肿瘤(PNETs)中的相关报道尚未得到充分研究。因此,我们研究了PNETs中PD-L1的表达、CD8+ TILs的浸润情况以及这两个因素的预后价值。

方法

本研究共纳入159例PNETs标本(35例典型类癌、2例不典型类癌、28例大细胞神经内分泌癌、94例小细胞肺癌)。采用免疫组织化学(IHC)检测这些病例中PD-L1的表达。肿瘤细胞表达≥5%或免疫细胞上有任何表达(>1%)的病例被视为阳性。使用全玻片数字成像分析浸润癌间质和肿瘤区域内的CD8+ TILs。对每个病例进行手动区域标注和机器细胞计数。

结果

72例(45.3%)观察到PD-L1阳性表达,其中9例(5.7%)仅在肿瘤细胞上表达,46例(28.9%)仅在免疫细胞上表达,17例(10.7%)在肿瘤细胞和免疫细胞上均有表达。PD-L1表达与坏死(p<0.001)、高病理分级(p<0.001)和组织学类型(p<0.001)相关。与总生存期(OS)(p=0.158)或无进展生存期(PFS)(p=0.315)无相关性。相反,较高的CD8+ T细胞密度与无血管侵犯(p=0.004)、组织学类型(p=0.005)、阴性淋巴结转移(p=0.005)和较低的临床分期(p=0.007)相关。此外,多因素分析显示CD8+间质TIL是OS改善(p=0.009)和PFS改善(p=0.002)的独立预后因素。

结论

约一半的PNETs表达PD-L1。大部分表达见于免疫细胞。PD-L1阳性表达与OS或PFS无相关性,而间质内较高的CD8+ TILs被证明是PNETs OS和PFS良好的独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2ca/5964902/f645064068ae/13000_2018_712_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验